Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Freeline to Present Data at the 2021 Virtual Congress of the European Association for .
Freeline TherapeuticsJanuary 26, 2021 GMT
LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that it will present two e-posters at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) taking place 3-5 February 2021. In addition, the Company will present data on its gene therapy programmes for Gaucher and Fabry Disease, in one oral platform presentation and three e-posters at the 17TH Annual WORLD